ALS Limited

The Business

ALS operates over 400 laboratories across 70 countries, providing testing services to the mining and life sciences industries. The Commodities division (39% of revenue) dominates global geochemical assaying, the analysis miners use to determine what is in the ground. Life Sciences (61% of revenue) spans pharmaceutical testing, food safety, and environmental analysis, including a growing PFAS contamination testing business. The defining structural advantage is network density: no competitor is within five years of replicating ALQ's global lab footprint at comparable scale, which creates switching costs for mining companies that need consistent, accredited results across multiple jurisdictions.

Recent Performance

FY26 delivered record results. Revenue grew 10.7% to $3,320 million, off a base that itself grew roughly 9% the prior year, so this represents genuine two-year compounding rather than recovery from a weak prior period. Underlying net profit reached $381 million. Minerals organic growth hit 20%, driven by elevated commodity prices (copper at its 100th historical percentile, gold at its 80th) and historically high explorer capital raisings. Life Sciences contributed steady mid-single-digit organic growth following the completion of the Nuvisan pharmaceutical testing integration in Europe. Cash conversion at 92% confirmed that reported earnings translated reliably into cash, with free cash flow per share of 96 cents providing comfortable coverage for the 42.5 cent fully franked dividend.

Outlook

The core analytical question is the durability of Minerals growth. Revenue growth is expected to decelerate materially from its FY26 peak as Minerals organic growth mean-reverts from 20% toward 3-5%, reflecting normalisation in exploration activity and commodity prices. EBITDA margins, which reached 25.1% in FY26, face compression as the Minerals mix tailwind fades. Life Sciences provides a structural offset, growing at a steady mid-single-digit rate underpinned by PFAS regulatory tailwinds and the maturing Nuvisan platform. Consensus forecasts embed roughly 8% annual revenue growth over the medium term; our analysis puts the sustainable rate closer to 5%, and that divergence is the primary source of disagreement between the market's current pricing and our assessment of intrinsic value.

Key Risks

Commodity cycle reversal is the primary risk. Copper sits at its 100th historical percentile and gold at its 80th, and junior explorer capital raisings, the main demand driver for geochemical testing, have historically shown an 18-24 month median boom-to-bust cycle. A sharp correction would compress Minerals margins significantly, given they have swung 520 basis points over the past three years. The hub lab program carries its own exposure: with $136 million of the $230 million build still to be deployed, a volume downturn before commissioning would leave ALQ with underutilised fixed capacity arriving at the wrong point in the cycle. Management has not disclosed break-even utilisation rates for these facilities. Persistently elevated interest rates represent a third risk, one with no company-specific mitigation: Australia's 10-year bond yield currently sits at its highest level in five years, and if rates remain elevated, the valuation relief that would otherwise accompany rate normalisation would not materialise.

What to Watch

• November 2026 H1 FY27 Minerals organic growth — The thesis-defining datapoint. The rate of organic growth in this result will indicate whether the commodity cycle is extending or beginning to revert, and will determine whether current consensus growth forecasts are achievable.
• CY2026-2027 RBA rate normalisation — A cutting cycle would provide valuation relief through discount rate compression. The timing and magnitude of any easing has a direct bearing on how much of the current price premium to peers is ultimately justified.
• 1-3 years PFAS regulation acceleration — Expanded US and EU mandates for per- and polyfluoroalkyl substances testing would add a structural, regulatory-driven growth layer to Environmental revenue that is independent of the commodity cycle.

Company Description

ALS Limited is a global laboratory testing company operating across two divisions. The Commodities division (39% of revenue, 33% EBIT margin) provides geochemical analysis, metallurgical testing, and mine-site laboratory services to the mining industry, with particular strength in gold and base metals assaying. The Life Sciences division (61% of revenue) encompasses three verticals: Environmental testing (water, soil, air quality, and the fast-growing PFAS contamination segment), Food and Pharmaceutical testing (including the recently integrated Nuvisan clinical trials platform in Europe), and Asset Care (industrial testing for energy infrastructure). The business generates revenue from over 400 laboratories across more than 70 countries, making it one of the most geographically dispersed testing networks in the world.

Where the Growth Is

Minerals testing within the Commodities division is the dominant growth engine, contributing 39% of group revenue at a 33% EBIT margin, the highest in the group. Organic growth reached 20% in FY26, propelled by record exploration spending and elevated commodity prices. That rate is expected to mean-revert toward 3-5% over the next three years as the commodity cycle normalises. That deceleration drives approximately 160 basis points of EBITDA margin compression from the FY26 peak. The structural offset is PFAS testing (currently around 6% of Environmental revenue, growing at mid-teens rates), which provides a regulatory-driven growth floor independent of commodity markets. The segment is small today but the regulatory pipeline, particularly in the United States and European Union, supports sustained above-group growth over the medium term.

Competitive Position

ALQ's competitive position in minerals testing is the strongest in the testing, inspection, and certification (TIC) industry. The company holds an estimated 35% global share of geochemical assaying, more than double its nearest competitor. This dominance rests on three reinforcing advantages. First, network density: 400-plus laboratories positioned near active mining regions worldwide, enabling fast turnaround that exploration companies value highly. Second, accreditation breadth: regulatory approvals across 70 jurisdictions create switching costs because miners need consistent, auditable results across borders. Third, the hub-and-spoke lab model currently being expanded through a $230 million investment program, which centralises high-volume processing in regional super labs while maintaining field collection points. No competitor could replicate this network within five years, even with unlimited capital, because the accreditation and client relationship layers require time to build that capital alone cannot compress.

Management & Capital Discipline

Management enforces a 15% ROIC hurdle for acquisitions and maintains a 57% dividend payout ratio with full franking. The $230 million hub lab program is being deployed in phases of roughly $45 million per year, with uncommitted stages pausable if volumes disappoint. This phasing matters given the cycle-peak timing of the investment. The Nuvisan acquisition, completed in FY24, transformed ALQ's European pharmaceutical testing capability and was delivered on schedule and within budget. Management achieved their own FY27 financial targets a year ahead of schedule. One candid observation: management takes slightly more credit than is fully warranted for what is substantially a commodity-cycle-driven earnings uplift. Internal analysis attributes roughly 35% of recent outperformance to execution and 65% to external tailwinds. Management has also not disclosed break-even utilisation rates for the hub labs despite $136 million of remaining committed spend, which limits investors' ability to independently assess the downside scenario.

Financial Position

The balance sheet is in strong condition. Net debt to EBITDA sits at 1.5 times, with 55% headroom to covenant limits. Interest coverage is 13.5 times. Cash conversion at 92% confirms that reported earnings translate reliably into cash. Capital expenditure ran at $263 million in FY26 (7.9% of revenue), elevated by the hub lab program. As that program completes over FY28-29, capex should normalise to 4-5% of revenue, which will convert a meaningful portion of current investment into free cash flow. The balance sheet can comfortably absorb a cyclical downturn without threatening the dividend or requiring equity. During the 2015-16 mining downturn, the Life Sciences division's 61% revenue contribution provided a buffer that prevented the kind of earnings collapse seen in pure-play mining services businesses, and the current balance sheet is in better condition than it was entering that period.